Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 378

Sort by

Sort Order Select

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Transplantation-Associated Microangiopathy (TAM) in Recipients of HLA-Haploidentical Hematopoietic Stem Cell Transplants Using Ptcy, CNI and MMF for GvHD Prophylaxis

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Haebe, MD, Veit Bücklein, MD, Heidrun Drolle, Ulf Schoenermarck, Wolfgang Hiddemann, PhD, Michael von Bergwelt, Johanna Tischer, MD

Blood (2019) 134 (Supplement_1): 1982.

https://doi.org/10.1182/blood-2019-130685

Published: 2019

Journal Articles

Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes

Siddhesh Arun Kalantri, MD, Akanksha Chichra, DNB, Amit Kumar Agrawal, MDMDcine, Lingaraj Nayak, MDDM MDcal Oncology, Avinash Bonda, MD DM, Sachin Punatar, MBBS,MDDM MDcal Oncology, Anant Gokarn, MD, Bhausaheb Bagal, MD DM, Libin J Mathew, Sadhana Kannan, MSc, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 1983.

https://doi.org/10.1182/blood-2019-125029

Published: 2019

Journal Articles

HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies- Two-Year Follow-up of Multicenter Study in Singapore

Li Mei Poon, MBBS, MRCP, FRCPath, Yeh Ching Linn, MBBS, MRCP, Poh Lin Tan, Ziyi LIM, Balamurugan Vellayappan, Rajat Bhattacharyya, Ah Moy Tan, MD, Lip Kun Tan, MBBS, FRCP, FRCPath, Teck Guan Soh, Colin Phipps Diong, Wing H. Leung, MD PhD, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 2039.

https://doi.org/10.1182/blood-2019-128014

Published: 2019

Journal Articles

Therapeutic Plasma Exchange (PLEX) in Thrombotic Microangiopathy (TMA): Experiences of an Inner-City Hospital over a Decade

Aakash Putta, MD MBBS, Hafeez Shaka, MD, Shristi Upadhyay Banskota, MD, Sunny R K Singh, MD, Sindhu Malapati, MD, Muhammad Zain Farooq, MD MBBS, Kumar Kunnal Batra, MD

Blood (2019) 134 (Supplement_1): 3691.

https://doi.org/10.1182/blood-2019-124265

Published: 2019

Journal Articles

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Karthik Gnanapandithan, MD MS, Prakash Kharel, MD, Alyssa Grimshaw, MSLIS, Smith Giri, MBBS

Blood (2019) 134 (Supplement_1): 3606.

https://doi.org/10.1182/blood-2019-132203

Published: 2019

Journal Articles

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Lauren M Panebianco, MD, Teresa Gentile, MD PhD

Blood (2019) 134 (Supplement_1): 4872.

https://doi.org/10.1182/blood-2019-128297

Published: 2019

Journal Articles

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Chris Wynick, MD MSc, BSc, Joanne Britto, MD BSc, Daniel Sawler, MD BSc, Arabesque Parker, MD, Mohammad Karkhaneh, PhD, Dawn Goodyear, MD, Haowei Linda Sun, MDFRCPC

Blood (2019) 134 (Supplement_1): 2379.

https://doi.org/10.1182/blood-2019-126354

Published: 2019

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive?

Sindhu Malapati, MD, Sunny R K Singh, MD, Rohit Kumar, MD, Jason Mouabbi, MD, Tarik Hadid, MD MS

Blood (2019) 134 (Supplement_1): 2353.

https://doi.org/10.1182/blood-2019-129375

Published: 2019

Journal Articles

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Yuji Yamada, MD, Hiroyuki Ohbe, MD MPH, Hideo Yasunaga, MD PhD, Yoshitaka Miyakawa, MD PhD

Blood (2019) 134 (Supplement_1): 2374.

https://doi.org/10.1182/blood-2019-125170

Published: 2019

Journal Articles

Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic Purpura

Jingrui (Jean) Sui, MD, Konstantine Halkidis, MD PhD, Nicole K. Kocher, Lance A. Williams, III, MD, Radhika Gangaraju, MD, Bryan K. Guillory, MD, Marisa B. Marques, MD, Wenjing Cao, MD,PhD, X. Long Zheng, MD, PhD

Blood (2019) 134 (Supplement_1): 1070.

https://doi.org/10.1182/blood-2019-131585

Published: 2019

Journal Articles

Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure

Stephanie C. Heidemann, MD, Brian Bursic, Sasan Zandi, MD PhD, Hongbing Li, PhD, Robert J Klaassen, MD FRCPC, Sharon Abish, MD, Meera Rayar, Vicky R. Breakey, BSc,MDFRCPC, Houtan Moshiri, PhD, Santhosh Dhanraj, PhD, Richard de Borja, PhD, Adam Shlien, PhD, John E. Dick, PhD, Yigal Dror, MDFRCPC, Sagi Abelson, PhD

Blood (2019) 134 (Supplement_1): 1223.

https://doi.org/10.1182/blood-2019-130534

Published: 2019

Journal Articles

Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies

Grace E Linder, MD, Steven Richard Sloan, MD PhD, Pavan Bendapudi, MD, Robert Makar, MD PhD

Blood (2019) 134 (Supplement_1): 1075.

https://doi.org/10.1182/blood-2019-130608

Published: 2019

Journal Articles

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Blood (2019) 134 (Supplement_1): 1082.

https://doi.org/10.1182/blood-2019-122665

Published: 2019

Journal Articles

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Mouhamed Yazan Abou-Ismail, MD, Yasmin Arafah, MD, Pingfu Fu, PhD, Shufen Cao, Alvin H. Schmaier, MD, Lalitha V. Nayak, MD

Blood (2019) 134 (Supplement_1): 1084.

https://doi.org/10.1182/blood-2019-123537

Published: 2019

Journal Articles

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Kazuya Sakai, MD, Masataka Kuwana, Hiroto Kojima, Hidenori Tanaka, Masayuki Kubo, Hideo Yagi, Masanori Matsumoto

Blood (2019) 134 (Supplement_1): 1085.

https://doi.org/10.1182/blood-2019-123927

Published: 2019

NARROW

A conceptual framework for managing iTTP

Redefining outcomes in immune TTP: an international working group consensus report

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Transplantation-Associated Microangiopathy (TAM) in Recipients of HLA-Haploidentical Hematopoietic Stem Cell Transplants Using Ptcy, CNI and MMF for GvHD Prophylaxis

Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes

HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies- Two-Year Follow-up of Multicenter Study in Singapore

Therapeutic Plasma Exchange (PLEX) in Thrombotic Microangiopathy (TMA): Experiences of an Inner-City Hospital over a Decade

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive?

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic Purpura

Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure

Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only